LongBio Pharma (Suzhou) Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	35.28	11.27	7.49
Research & Development	126.62	98.08	73.91
Other Operating Expenses	2.41	0.05	0.15
Operating Expenses	164.31	109.4	81.55
Operating Income	-164.31	-109.4	-81.55
Interest Expense	-16.86	-30.99	-16.52
Interest & Investment Income	1.35	1.33	0.77
Currency Exchange Gain (Loss)	-	-	0.02
Other Non Operating Income (Expenses)	0.01	0.04	0.51
EBT Excluding Unusual Items	-179.81	-139.02	-96.78
Gain (Loss) on Sale of Investments	1.24	0.5	-
Other Unusual Items	2.98	1.2	1.04
Pretax Income	-175.58	-137.32	-95.74
Income Tax Expense	-	-	0.04
Net Income	-175.58	-137.32	-95.78
Net Income to Common	-175.58	-137.32	-95.78
Shares Outstanding (Basic)	57	47	43
Shares Outstanding (Diluted)	57	47	43
Shares Change (YoY)	19.32%	10.91%	-
EPS (Basic)	-3.10	-2.89	-2.24
EPS (Diluted)	-3.10	-2.89	-2.24
Free Cash Flow	-125.43	-110.27	-63.34
Free Cash Flow Per Share	-2.21	-2.32	-1.48
EBITDA	-160.48	-105.86	-78.67
D&A For EBITDA	3.83	3.54	2.89
EBIT	-164.31	-109.4	-81.55